МирNew Data at ECTRIMS Highlight Positive Benefit-Risk Profile of Mavenclad in Relapsing Multiple SclerosisМихаэль Шварцман29.10.2017
МирMerck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017Михаэль Шварцман21.10.2017
МирFour-year contract covers 10 UEFA National Team Football competitions and over 500 matches, including UEFA EURO 2020(TM)Михаэль Шварцман20.10.201722.10.2017